{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:19:13Z","timestamp":1791109153808,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.jhep.2008.04.021","type":"journal-article","created":{"date-parts":[[2008,6,3]],"date-time":"2008-06-03T15:45:33Z","timestamp":1212507933000},"page":"528-536","source":"Crossref","is-referenced-by-count":69,"title":["Market uptake of new antiviral drugs for the treatment of hepatitis C"],"prefix":"10.1016","volume":"49","author":[{"given":"Beate","family":"Lettmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"M\u00fchlberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Schwarzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaby","family":"Sroczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davene","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2008.04.021_bib1","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 \u2013 June 10\u201312, 2002. Hepatology 2002;36:S3\u2013S20.","DOI":"10.1002\/hep.1840360703"},{"key":"10.1016\/j.jhep.2008.04.021_bib2","unstructured":"M\u00fchlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. Burden of disease related to HCV-infections in Europe. [Oral presentation]. ESCAIDE Conference, Stockholm, Sweden, October, 18\u201320, 2007 [Abstract no. 06.2]."},{"key":"10.1016\/j.jhep.2008.04.021_bib3","doi-asserted-by":"crossref","unstructured":"EASL International Consensus Conference on hepatitis C. Paris, 26\u201327 February 1999. Consensus statement. J Hepatol 1999;31:3\u20138.","DOI":"10.1016\/S0168-8278(99)80367-5"},{"key":"10.1016\/j.jhep.2008.04.021_bib4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/bmj.323.7322.1151","article-title":"Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials","volume":"323","author":"Kjaergard","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2008.04.021_bib5","first-page":"CD002234","article-title":"Ribavirin with or without alpha interferon for chronic hepatitis C","author":"Kjaergard","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2008.04.021_bib6","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: efficacy, side effects, and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2008.04.021_bib7","unstructured":"Brady B, Siebert U, Sroczynski G, Murphy G, Husereau DR, Sherman M, et al. Pegylated Interferon combined with Ribavirin for chronic hepatitis C virus infection: an economic evaluation [Technology Report No. 82]. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health (CADTH); 2007."},{"key":"10.1016\/j.jhep.2008.04.021_bib8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2008.04.021_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00384-005-0038-9","article-title":"Current therapy for hepatitis C","volume":"22","author":"Friedrich-Rust","year":"2007","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.jhep.2008.04.021_bib10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Int Med"},{"key":"10.1016\/j.jhep.2008.04.021_bib11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2008.04.021_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1542-3565(05)00247-8","article-title":"Update on chronic hepatitis C","volume":"3","author":"Wong","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2008.04.021_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.52.3.425","article-title":"Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"52","author":"Siebert","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2008.04.021_bib14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1365-2036.2003.01453.x","article-title":"A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C","volume":"17","author":"Buti","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2008.04.021_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00019053-200422040-00004","article-title":"Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C","volume":"22","author":"Sullivan","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jhep.2008.04.021_bib16","unstructured":"British Liver Trust, University of Southhampton [homepage on the Internet]. The UK vs. Europe: Losing the Fight Against Hepatitis C. p. 1\u201312 [published 2005; cited 2007 Jan 15]. Available from: http:\/\/www.hepcuk.info."},{"key":"10.1016\/j.jhep.2008.04.021_bib17","unstructured":"European Liver Patients Association (ELPA). World Hepatitis Awareness Day: Health Care Access and Public Policy for the Prevention and Care of Viral Hepatitis in Europe. A report of the European Liver Patients Association. Bruxelles; 2006."},{"key":"10.1016\/j.jhep.2008.04.021_bib18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1525-1497.2005.0161.x","article-title":"Barriers to the treatment of hepatitis C. Patient, provider, and system factors","volume":"20","author":"Morrill","year":"2005","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jhep.2008.04.021_bib19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1155\/2002\/205482","article-title":"Motion \u2013 the available treatments for hepatitis C are cost effective: arguments for the motion","volume":"16","author":"Terrault","year":"2002","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2008.04.021_bib20","unstructured":"Central and Eastern European Harm Reduction Network (CEEHRN). Hepatitis C and drug use in the new EU member states and neighborhood: Consultation Report. Vilnius, Lithuania; 2006."},{"key":"10.1016\/j.jhep.2008.04.021_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid0701.010101","article-title":"Emerging infectious diseases in Russia","volume":"7","author":"Netesov","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jhep.2008.04.021_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2458-6-3","article-title":"Variation in Hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom","volume":"6","author":"Parkes","year":"2006","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhep.2008.04.021_bib23","unstructured":"The Federal Bureau of Prisons (BOP) [homepage on the Internet]. Guidelines for the Prevention and Treatment of Viral Hepatitis. p. 1\u201376 [published 2005; cited 2006 Oct 8]. Available from: http:\/\/www.bop.gov\/news\/PDFs\/hepatitis.pdf."},{"key":"10.1016\/j.jhep.2008.04.021_bib24","unstructured":"Rote Liste [database on the Internet]. [Copegus(R) 200mg tablets] [German]. p. 1\u201310 [updated 2005 July; cited 2006 January 15]. Available from: http:\/\/www.rote-liste.de."},{"key":"10.1016\/j.jhep.2008.04.021_bib25","unstructured":"Rote Liste [database on the Internet]. [Rebetol (R) 200mg hard capsule] [German]. p. 1\u201311 [updated 2006 April; cited 2007 Jun 2]. Available from: http:\/\/www.rote-liste.de."},{"key":"10.1016\/j.jhep.2008.04.021_bib26","unstructured":"Roche Products Ltd [homepage on the Internet]. Copegus 200mg. p. 1\u201323 [updated 2007 January 24; cited 2007 Jan 13]. Available from: http:\/\/emc.medicines.org.uk\/emc\/assets\/c\/html\/."},{"key":"10.1016\/j.jhep.2008.04.021_bib27","unstructured":"Schering-Plough Ltd [homepage on the Internet]. Rebetol 200mg hard capsules. p. 1\u201323 [updated 2007 March 26; cited 2007 March 28]. Available from: http:\/\/emc.medicines.org.uk\/emc\/assets\/c\/html\/."},{"key":"10.1016\/j.jhep.2008.04.021_bib28","unstructured":"Roche Products Ltd. [homepage on the Internet]. Roferon-A Cartridge. p. 1\u20138 [updated 2005 November 1; cited 2007 February 13]. Available from: http:\/\/www.rocheuk.com."},{"key":"10.1016\/j.jhep.2008.04.021_bib29","unstructured":"IMS Health. Sales Data. IMS MIDAS\/Q1 2006; 2006."},{"key":"10.1016\/j.jhep.2008.04.021_bib30","unstructured":"F. Hoffman La Roche Ltd. HCV Management Insights. Patient Chart Audit (Wave 2). Global. 2006."},{"key":"10.1016\/j.jhep.2008.04.021_bib31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KDa)\/ribavirin","volume":"43","author":"Ferenci","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.04.021_bib32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C","volume":"38","author":"Davis","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.04.021_bib33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/00365540310013252","article-title":"Chronic hepatitis C: updated Swedish consensus","volume":"35","author":"Wejstal","year":"2003","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jhep.2008.04.021_bib34","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1111\/j.1572-0241.2003.t01-1-08735.x","article-title":"Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C","volume":"98","author":"Wong","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2008.04.021_bib35","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1055\/s-2004-813444","article-title":"Standard treatment of acute and chronic hepatitis C","volume":"42","author":"Zeuzem","year":"2004","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2008.04.021_bib36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00042737-200105000-00003","article-title":"Prevalence of hepatitis C virus infection in the general population of northern Spain","volume":"13","author":"Riestra","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2008.04.021_bib37","unstructured":"Eurasian Harm Reduction Network (EHRN). HCV Infection in Europe. p. 1\u201316 [updated 2007 Oct 1; cited 2007 Oct 15]. Available from:http:\/\/www.ceehrn.org\/EasyCEE\/sys\/files\/HCV%20in%20selected%20countries%20of%20Europe_Report_FINAL_SEPTEMBER.pdf."},{"key":"10.1016\/j.jhep.2008.04.021_bib38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2807\/esm.08.05.00410-en","article-title":"Surveillance of screening for hepatitis C through the laboratory network RENA-VHC, France, 2000\u20132001","volume":"8","author":"Meffre","year":"2003","journal-title":"Euro Surveillance: Bulletin European sur les Maladies Transmissibles = European Communicable Disease Bulletin"},{"key":"10.1016\/j.jhep.2008.04.021_bib39","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1086\/427456","article-title":"Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries","volume":"40 Suppl 5","author":"Reimer","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2008.04.021_bib40","unstructured":"PanEuropean Hepatitis C Expert Panel. Expert opinions (October 2007). 2007."},{"key":"10.1016\/j.jhep.2008.04.021_bib41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00019053-200624070-00005","article-title":"Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies","volume":"24","author":"Wong","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jhep.2008.04.021_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11110","article-title":"Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation","volume":"11","author":"Shepherd","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jhep.2008.04.021_bib43","unstructured":"Siebert U, Sroczynski G. On behalf of the German Hepatitis C Model (GEHMO) Group and the HTA Expert Panel on Hepatitis C. Antiviral therapy for patients with chronic hepatitis C in Germany. Evaluation of effectiveness and cost-effectiveness of initial combination therapy with Interferon\/Peginterferon plus Ribavirin. Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security. Cologne, Germany: DIMDI; 2003."},{"key":"10.1016\/j.jhep.2008.04.021_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2893.1995.tb00045.x","article-title":"The distribution of hepatitis C virus genotypes in Turkish patients","volume":"2","author":"Abacioglu","year":"1995","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2008.04.021_bib45","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s00705-004-0363-2","article-title":"Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients","volume":"149","author":"Bozdayi","year":"2004","journal-title":"Arch Virol"},{"key":"10.1016\/j.jhep.2008.04.021_bib46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020161818764","article-title":"Molecular characterization of a full genome Turkish hepatitis C virus 1b isolate (HCV-TR1): a predominant viral form in Turkey","volume":"25","author":"Yildiz","year":"2002","journal-title":"Virus Genes"},{"key":"10.1016\/j.jhep.2008.04.021_bib47","unstructured":"Oprisoreanu A, Szmal C, Thiers V, Oprisan G. Comparative analysis of three different regions of hepatitis C virus for genotyping Romanian strains [Abstract No.: 1733_928]. In: Seventeenth European Congress of Clinical Microbiology and Infectious Diseases ICC; 2007; Munich, Germany, March 31\u2013April 4; 2007."},{"key":"10.1016\/j.jhep.2008.04.021_bib48","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/00365549609037919","article-title":"Prevalence of hepatitis C genotypes among patients with chronic hepatitis C in Norway. Construct Group","volume":"28","author":"Bell","year":"1996","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jhep.2008.04.021_bib49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/003655200750023822","article-title":"Leukocyte interferon-alpha in the treatment of chronic hepatitis C in Finland","volume":"35","author":"Ebeling","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2008.04.021_bib50","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/00365520310008115","article-title":"Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre","volume":"39","author":"Hollander","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2008.04.021_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0928-0197(96)00242-5","article-title":"Hepatitis C genotypes in Finland determined by RFLP","volume":"7","author":"Pohjanpelto","year":"1996","journal-title":"Clin Diagn Virol"},{"key":"10.1016\/j.jhep.2008.04.021_bib52","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/00365549950163770","article-title":"Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings","volume":"31","author":"Westin","year":"1999","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jhep.2008.04.021_bib53","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1128\/JCM.41.3.1091-1100.2003","article-title":"Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients","volume":"41","author":"Corbet","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2008.04.021_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2893.2006.00795.x","article-title":"Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?","volume":"14","author":"Harris","year":"2007","journal-title":"J Vir Hepat"},{"key":"10.1016\/j.jhep.2008.04.021_bib55","first-page":"12","article-title":"Chronic hepatitis C \u2013 changes since the Austrian Consensus of 2005 \u2013 the tailored therapy","volume":"4","author":"Ferenci","year":"2006","journal-title":"J Gastroenterol Hepatol Erkr"},{"key":"10.1016\/j.jhep.2008.04.021_bib56","first-page":"218","article-title":"Is shorter treatment with Peginterferon-alpha 2a (40kDa) (Pegasys(R)) plus Ribavirin (COPEGUS(R)) possible in genotype 1 superresponders? Preliminary results of a prospective, randomized trial","volume":"42","author":"Ferenci","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.04.021_bib57","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7326\/0003-4819-136-4-200202190-00008","article-title":"Surprisingly small effect of antiviral treatment in patients with hepatitis C","volume":"136","author":"Falck-Ytter","year":"2002","journal-title":"Ann Int Med"},{"key":"10.1016\/j.jhep.2008.04.021_bib58","unstructured":"Anonymous. Chronic hepatitis C from the viewpoint of the patients. There are many causes for the quality of life of patients with chronic hepatitis C to be impaired. But there also exist many possibilities to change it. MMW Fortschr Med 2002;144:59."},{"key":"10.1016\/j.jhep.2008.04.021_bib59","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1572-0241.2006.00544.x","article-title":"Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life","volume":"101","author":"Danoff","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2008.04.021_bib60","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00007435-199804000-00010","article-title":"Hepatitis C transmission and the underreporting of stigmatized behaviors","volume":"25","author":"Friedman","year":"1998","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.jhep.2008.04.021_bib61","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2003.12.014","article-title":"The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C","volume":"40","author":"Hassanein","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2008.04.021_bib62","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2893.2003.00482.x","article-title":"Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C","volume":"11","author":"Perrillo","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2008.04.021_bib63","first-page":"222A","article-title":"Patient-based health-related quality of life in different stages of chronic hepatitis C","volume":"34","author":"Siebert","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.04.021_bib64","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.20659","article-title":"Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment","volume":"41","author":"Spiegel","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2008.04.021_bib65","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/01612840490486782","article-title":"A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: does nursing play a role?","volume":"25","author":"Strinko","year":"2004","journal-title":"Issues Ment Health Nurs"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827808003516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827808003516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T21:30:31Z","timestamp":1557610231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827808003516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0168827808003516"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2008.04.021","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}